Grand Pharma Acquires Rights to Mitral Valve Replacement Device
publication date: Jan 27, 2022
Hong Kong's Grand Pharmaceutical acquired greater China rights to the Saturn Transcatheter Mitral Valve Replacement (TMVR) system developed by Milan's InnovHeart. Grand Pharma will make an equity investment in InnovHeart, plus pay upfront licensing fees, milestone payments and structured royalties. InnovHeart said the transaction, including other investors' participation in the Series C financing, would total up to $55 million. Grand Pharma led the Series C equity round. It was joined by existing investors Genextra, Panakes Partners and Indaco Venture Partners. More details....
Stock Symbol: (HK: 00512)
Share this with colleagues:
To gain access to the members only content click here to subscribe.
You will be given immediate access to premium content on the site.